Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Growth in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,370,000 shares, an increase of 25.7% from the December 31st total of 2,680,000 shares. Based on an average daily trading volume, of 286,800 shares, the short-interest ratio is currently 11.8 days. Approximately 7.4% of the company's shares are short sold.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Oppenheimer boosted their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an "outperform" rating in a report on Thursday, November 14th. JMP Securities initiated coverage on shares of Astria Therapeutics in a research note on Friday. They issued an "outperform" rating and a $26.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Thursday, January 23rd. Finally, Citizens Jmp raised shares of Astria Therapeutics to a "strong-buy" rating in a report on Friday. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Astria Therapeutics has an average rating of "Buy" and an average price target of $25.67.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS traded down $0.43 during trading hours on Monday, hitting $7.43. 247,921 shares of the company's stock traded hands, compared to its average volume of 306,053. Astria Therapeutics has a 52 week low of $7.16 and a 52 week high of $16.90. The company has a market cap of $419.27 million, a price-to-earnings ratio of -3.56 and a beta of 0.68. The company's fifty day simple moving average is $8.88 and its two-hundred day simple moving average is $10.40.

Institutional Trading of Astria Therapeutics

A number of hedge funds have recently bought and sold shares of ATXS. FMR LLC lifted its position in shares of Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company's stock worth $86,123,000 after purchasing an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. grew its holdings in Astria Therapeutics by 1.2% during the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company's stock valued at $56,208,000 after purchasing an additional 61,457 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Astria Therapeutics by 23.1% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company's stock worth $44,040,000 after acquiring an additional 750,000 shares during the last quarter. Millennium Management LLC grew its stake in shares of Astria Therapeutics by 13.5% in the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company's stock worth $16,763,000 after acquiring an additional 218,518 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Astria Therapeutics by 152.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company's stock worth $3,460,000 after buying an additional 189,727 shares in the last quarter. 98.98% of the stock is owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.